Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET

Company Participants

Helen Torley - President & Chief Executive Officer

Nicole LaBrosse - Chief Financial Officer

Conference Call Participants

Charles Duncan - Cantor Fitzgerald

Mike DiFiore - Evercore

Corinne Jenkins - Goldman Sachs

Jessica Fye - JPM Chase

Anita Dushyanth - Berenberg Capital Markets

Operator

Good afternoon. My name is Emma, and I will be your conference operator today. At this time, I would like to welcome everyone to the Halozyme First Quarter 2022 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.

Don Sharlene [ph], you may begin your conference.

Unidentified Company Representative

Good afternoon, and welcome to our first quarter 2022 financial results conference call. In addition to our press release issued today after the close, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website.

Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Nicole LaBrosse, our Chief Financial Officer, who will review our financial results for the first quarter.

On today's call, both GAAP and non-GAAP financial measures will be discussed. The non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.

During the call, we will be making forward-looking statements. I refer you to our SEC filings for a full listing of the risks and uncertainties.

I'll now turn the call over to our CEO, Helen Torley.

Helen Torley

Thank you, Don. 2022 is also a very strong start for Halozyme from both an operational and a capital allocation standpoint. In April, we announced our planned acquisition of Antares Pharma, which is on track to close in the second quarter. This acquisition strengthens Halozyme's position as an industry leader in drug delivery and provides revenue growth and diversification.

Halozyme and Antares also share a common culture built around the same mission innovating to improve the lives of patients. We look forward to building an even stronger company together with our Antares colleagues and are excited about the greater impact we will continue to drive for patients, customers and shareholders.

Nicole and her finance team have secured financing to support the acquisition with access to very favorable debt structure. She will provide more color around that during her remarks. As we progress through the completion of the Antares acquisition, we've continued our demonstration of executional excellence and delivered on the key first quarter milestones.